Cobelens FG - Search Results

1

MDR-TB treatment as prevention: The projected population-level impact of expanded treatment for multidrug-resistant tuberculosis.

Kendall EA, Azman AS, Cobelens FG, Dowdy DW. Kendall EA, et al. Among authors: cobelens fg. PLoS One. 2017 Mar 8;12(3):e0172748. doi: 10.1371/journal.pone.0172748. eCollection 2017. PLoS One. 2017. PMID: 28273116 Free PMC article.

2

Rates of anti-tuberculosis drug resistance in Kampala-Uganda are low and not associated with HIV infection.

Lukoye D, Cobelens FG, Ezati N, Kirimunda S, Adatu FE, Lule JK, Nuwaha F, Joloba ML. Lukoye D, et al. Among authors: cobelens fg. PLoS One. 2011 Jan 10;6(1):e16130. doi: 10.1371/journal.pone.0016130. PLoS One. 2011. PMID: 21249225 Free PMC article.

3

Which new diagnostics for tuberculosis, and when?

Cobelens F, van den Hof S, Pai M, Squire SB, Ramsay A, Kimerling ME; Evidence for Scale-up Group. Cobelens F, et al. J Infect Dis. 2012 May 15;205 Suppl 2:S191-8. doi: 10.1093/infdis/jis188. Epub 2012 Apr 3. J Infect Dis. 2012. PMID: 22476716

4

Tuberculosis control in crisis: economic honesty and comparative effectiveness.

Dowdy D, Vassall A, Cobelens F. Dowdy D, et al. Int J Tuberc Lung Dis. 2012 Aug;16(8):1131-2. doi: 10.5588/ijtld.12.0270. Int J Tuberc Lung Dis. 2012. PMID: 22762428 No abstract available.

5

Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action.

Wells WA, Boehme CC, Cobelens FG, Daniels C, Dowdy D, Gardiner E, Gheuens J, Kim P, Kimerling ME, Kreiswirth B, Lienhardt C, Mdluli K, Pai M, Perkins MD, Peter T, Zignol M, Zumla A, Schito M. Wells WA, et al. Among authors: cobelens fg. Lancet Infect Dis. 2013 May;13(5):449-58. doi: 10.1016/S1473-3099(13)70025-2. Epub 2013 Mar 24. Lancet Infect Dis. 2013. PMID: 23531393 Free PMC article. Review.

6

For whom the bell tolls: isoniazid preventive therapy and tuberculosis drug resistance.

Cobelens FG. Cobelens FG. Sci Transl Med. 2013 Apr 10;5(180):180fs12. doi: 10.1126/scitranslmed.3006094. Sci Transl Med. 2013. PMID: 23576813

7

Multidrug-resistant TB in Zambia: review of national data from 2000 to 2011.

Kapata N, Chanda-Kapata P, Bates M, Mwaba P, Cobelens F, Grobusch MP, Zumla A. Kapata N, et al. Trop Med Int Health. 2013 Nov;18(11):1386-91. doi: 10.1111/tmi.12183. Epub 2013 Sep 11. Trop Med Int Health. 2013. PMID: 24033538 Free article.

8

Cost-effectiveness of rapid susceptibility testing against second-line drugs for tuberculosis.

Dowdy DW, van't Hoog A, Shah M, Cobelens F. Dowdy DW, et al. Int J Tuberc Lung Dis. 2014 Jun;18(6):647-54. doi: 10.5588/ijtld.13.0776. Int J Tuberc Lung Dis. 2014. PMID: 24903933 Free PMC article.

9

Impact and cost-effectiveness of current and future tuberculosis diagnostics: the contribution of modelling.

Dowdy DW, Houben R, Cohen T, Pai M, Cobelens F, Vassall A, Menzies NA, Gomez GB, Langley I, Squire SB, White R; TB MAC meeting participants. Dowdy DW, et al. Int J Tuberc Lung Dis. 2014 Sep;18(9):1012-8. doi: 10.5588/ijtld.13.0851. Int J Tuberc Lung Dis. 2014. PMID: 25189546 Free PMC article.

10

Drivers and trajectories of resistance to new first-line drug regimens for tuberculosis.

Shrestha S, Knight GM, Fofana M, Cohen T, White RG, Cobelens F, Dowdy DW. Shrestha S, et al. Open Forum Infect Dis. 2014 Aug 30;1(2):ofu073. doi: 10.1093/ofid/ofu073. eCollection 2014 Sep. Open Forum Infect Dis. 2014. PMID: 25734143 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

271 results

Search Page

Filters